Bromocriptine

한글명:Bromocriptine

카스 번호25614-03-3

상품명:Bromocriptine

CBNumberCB6136426

분자식C32H40BrN5O5

포뮬러 무게654.59

MOL 파일25614-03-3.mol

화학적 성질

녹는점	215-218° (dec)
알파	D20 -195° (c = 1 in methylene chloride)
끓는 점	891.3±65.0 °C(Predicted)
밀도	1.2734 (rough estimate)
굴절률	1.6400 (estimate)
산도 계수 (pKa)	pKa 4.90±0.05(80% MCS t = RT) (Uncertain)
수용성	2.07mg/L(온도 미공개)
CAS 데이터베이스	25614-03-3(CAS DataBase Reference)

위험 및 안전 성명

독성

An ergot alkaloid derivative that exhibits potent dopamine agonist properties, particularly at D2 dopamine receptors. Bromocriptine, like dopamine, inhibits prolactin release from the pituitary and so is used in endocrine disorders, such as hyperprolactinemia. It is also used in the treatment of Parkinson’s disease. A large “first-pass” effect is seen with bromocriptine, and peak concentrations occur about 1.5-3 h after ingestion, with a half-life of about 3 h. Nausea, vomiting, and orthostatic hypotension are among the acute adverse effects. Long-term use has been associated with dyskinesias, constipation, psychoses, digital spasm, and erythromelalgia. The LD50 in rabbits exceeds 1 g/kg, p.o., and 12 mg/kg, i.v.

그림문자(GHS)

Bromocriptine 화학적 특성, 용도, 생산

화학적 성질
Crystals.
용도
Bromocriptine, a dopaminomimetic that is a dopamine D2 receptor agonist, possesses expressed antiparkinsonian activity. It is used for treating all phases of idiopathic and postencephalic Parkinsonism.
정의
An semisynthetic ergotamine alkaloid derivative and powerful dopamine D2 agonist. It inhibits prolactin secretion and release from the pituitary and retards tumor growth.
World Health Organization (WHO)
Bromocriptine, a semisynthetic ergot alkaloid derivative and prolactin inhibitor was introduced into medicine in 1976. It is used in the prevention of lactation, but because of the risk of rebound effect and since only 10% of women benefit therapeutically from such intervention, the United States Food and Drug Administration has requested manufacturers to no longer indicate preparations containing bromocriptine for this purpose. The World Health Organization is not aware of similar action having been taken elsewhere.
위험도
Poison; teratogen; developmental abnor- malities of the respiratory system,musculoskeletal system, rogenital system, craniofacial area, and body wall; teratogen; mutagen; questionable car- cinogen; tumorigen; causes nausea, vomiting, orthostatic hypotension; constipation, dyskinesias, psychoses, digital spasm, erythromelalgia.
Mechanism of action
Bromocriptine is absorbed after oral administration, but approximately 90% of a dose undergoes extensive first-pass hepatic metabolism, with the remainder hydrolyzed in the liver to inactive metabolites that are eliminated mostly in the bile. The half-life is relatively short (~3 hours).
Clinical Use
Bromocriptine is an ergot peptide derivative that is a partial agonist at D1-type and a full agonist at D2-type postsynaptic dopamine receptors, usually given in combination with levodopa therapy. It was the first direct dopamine receptor agonist used in treatment of Parkinson's disease after its development as an inhibitor of prolactin release (via activation of anterior pituitary D2 receptors). At low doses (typically 1–5 mg/day), bromocriptine is an effective prolactin inhibitor, and at higher doses (typically 10–20 mg/day), the antiparkinsonism and mood-elevating effects of bromocriptine become apparent.
부작용
Bromocriptine has a number of undesirable side effects, even causing mental disturbances in long-term use.

Bromocriptine 준비 용품 및 원자재

Bromocriptine 공급 업체

Bromocriptine 관련 검색

Send Inquriy